Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $33.59 Average Price Target from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $33.5909.

A number of analysts recently commented on ROIV shares. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen increased their price target on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 price target on Roivant Sciences in a research report on Thursday, May 21st. Finally, Sanford C. Bernstein started coverage on Roivant Sciences in a research report on Friday, March 20th. They set an “outperform” rating and a $35.00 price target for the company.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $28.41 on Thursday. The business’s 50 day simple moving average is $28.87 and its two-hundred day simple moving average is $25.88. The firm has a market cap of $20.43 billion, a P/E ratio of -47.35 and a beta of 1.13. Roivant Sciences has a 52-week low of $10.70 and a 52-week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. The firm had revenue of $2.52 million during the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the business posted ($0.29) earnings per share. On average, equities analysts forecast that Roivant Sciences will post -1.83 earnings per share for the current fiscal year.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 41,861 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the transaction, the director directly owned 15,804 shares of the company’s stock, valued at approximately $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Jennifer Humes sold 13,538 shares of the stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the transaction, the chief accounting officer directly owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 945,173 shares of company stock valued at $27,654,456 in the last three months. 10.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds have recently made changes to their positions in ROIV. Jones Financial Companies Lllp grew its position in shares of Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares in the last quarter. SBI Securities Co. Ltd. grew its position in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP grew its position in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of Roivant Sciences in the fourth quarter valued at $47,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.